Safety update of etanercept treatment for moderate to severe plaque psoriasis
Anna Campanati, Federico Diotallevi, Emanuela Martina, Matteo Paolinelli, Giulia Radi, Annamaria Offidani
Abstract
: ETN has a favorable safety profile, and its use should be largely considered in psoriatic patients. Caution should be recommended in case of chronic heart failure, autoimmune disease, previous malignancies, familial history of demyelinating diseases, latent TBC infection, chronic HBV and HCV infection or HIV.
Topics & Concepts
MedicineEtanerceptPsoriasisAdverse effectIntensive care medicineSafety profilePsoriatic arthritisDiseaseDermatologyInternal medicineRheumatoid arthritisPsoriasis: Treatment and PathogenesisAutoimmune and Inflammatory Disorders ResearchRheumatoid Arthritis Research and Therapies